Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 6
Submit an article Journal homepage
174
Views
0
CrossRef citations to date
0
Altmetric
Systematic Review

Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?

Federica Tomaoa Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, ItalyView further author information
,
Giuseppe Carusob Department of Maternal and Child Health and Urological Sciences, Policlinico “Umberto I”, University of Rome “Sapienza”, Rome, ItalyCorrespondence[email protected]
View further author information
,
Lucia Musacchiob Department of Maternal and Child Health and Urological Sciences, Policlinico “Umberto I”, University of Rome “Sapienza”, Rome, ItalyView further author information
,
Violante Di Donatob Department of Maternal and Child Health and Urological Sciences, Policlinico “Umberto I”, University of Rome “Sapienza”, Rome, ItalyView further author information
,
Maria Cristina Petrellac Department of Medical Oncology, AOUC University Hospital Careggi, Florence, ItalyView further author information
,
Monica Verricod Department of Medical Oncology Unit A, Policlinico Umberto I, University of Rome “Sapienza”, Rome, ItalyView further author information
,
Silverio Tomaod Department of Medical Oncology Unit A, Policlinico Umberto I, University of Rome “Sapienza”, Rome, ItalyView further author information
,
Pierluigi Benedetti Panicib Department of Maternal and Child Health and Urological Sciences, Policlinico “Umberto I”, University of Rome “Sapienza”, Rome, ItalyView further author information
,
Ludovico Muziib Department of Maternal and Child Health and Urological Sciences, Policlinico “Umberto I”, University of Rome “Sapienza”, Rome, ItalyView further author information
&
Innocenza Palaiab Department of Maternal and Child Health and Urological Sciences, Policlinico “Umberto I”, University of Rome “Sapienza”, Rome, ItalyView further author information
 show all
Pages 641-650 | Received 30 Aug 2020, Accepted 05 Feb 2021, Published online: 15 Feb 2021
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

ABSTRACT

Introduction: Advanced, persistent or recurrent cervical cancer in patients not amenable to curative surgery or radiotherapy predicts a dismal prognosis. Systemic chemotherapy based on paclitaxel/cisplatin ± bevacizumab is the current standard of care. However, once progression occurs, the possibility of alternative treatment options is very limited.

Areas covered: The usefulness of capecitabine has been well-established against several cancer types, including head and neck, breast, and colorectal cancer. This review covers current literature evidence on the clinical efficacy and safety of capecitabine in cervical cancer treatment, either as monotherapy or combined with other agents or chemo-radiotherapy.

Expert opinion: Recent clinical data, albeit scant, suggested a promising role for capecitabine both as monotherapy in patients with platinum-resistant cervical cancer and in combination with cisplatin in chemotherapy-naïve patients with metastatic or recurrent cervical cancer. In our opinion, capecitabine, especially in combination regimens, could represent a valid treatment option and further research is warranted to better understand its effectiveness in these challenging patients.

Article highlights

  • Advanced, persistent or recurrent cervical cancer poses a difficult therapeutic challenge.

  • No confirmed second-line treatments are available after platinum resistance or intolerance.

  • Oral capecitabine, alone or in combination, could represent an effective and feasible alternative option.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 752.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.